This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Metformin, Ivermectin, and Fluvoxamine for Covid-19

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

Additional treatments for early SARS-CoV-2 infection are needed. Metformin, ivermectin, and fluvoxamine have limited evidence of efficacy in this context. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account